;
;
(, , , );
;
.
9) :
2-4 , , ;
3 1 ;
[12];
5 6 .
13. -.
14. - .
15. , :
| NB | ||
| RW | ||
16. :
1) , , , .
2) , , .. .
3) , , - .
4) , , , .
17. :
18. : , 2, .. .
19. : 3 .
20. :
1) Lawrie TA, Nordin A, Chakrabarti M, Bryant A, Kaushik S, Pepas L /Medical and surgical treatments for usual-type vulval intraepithelial neoplasia (uVIN)/ Cochrane library/ 5 January 2016.
2) Terlou A, et al. / Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow-up of a randomized clinical trial/ Department of Obstetrics and Gynecology, Erasmus MC University Medical Centre, Rotterdam, Gynecol Oncol., 121(1):157-62. Epub 2011 Jan 15/ Randomized Controlled Trial.
|
|
|
3) Amanda Tristram, et al./Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RTVIN):a multicentre, open-label, randomised, phase 2 trial/ Lancet Oncol 2014/www.thelancet.com/oncology Published online October 8, 2014 http://dx.doi.org/10.1016/S1470-2045(14)70456-5
4) Sai L Daayana/ PHASE II TRIAL OF IMIQUIMOD AND HPVTHERAPEUTIC VACCINATION IN PATIENTS WITHVULVAL INTRAEPITHELIAL NEOPLASIA/ A thesis submitted to The University of Manchester for the degree ofDoctor of Medicinein the Faculty of Medical and Human sciences, School of Medicine 2010.
5) Stier, Elizabeth A, et al. /Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women/ IDS: 20 February 2013 - Volume 27 - Issue 4 - p 545551.
6) Bell MC, et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol 2000;78:123-9.
7) Naik R1, Nixon S, Lopes A, Godfrey K, Hatem MH, Monaghan JM./ A randomized phase II trial of indole-3-carbinol in the treatment of vulvar intraepithelial neoplasia/ See comment in PubMed Commons belownt J Gynecol Cancer. 2006 Mar-Apr;16(2):786-90.
8) Krebs HB/ Prophylactic topical 5-fluorouracil following treatment of human papillomavirus-associated lesions of the vulva and vagina/Obstet Gynecol.1986 Dec;68(6):837-4.
9) Lucy J C Smyth et al. /Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination./ Clin Cancer Res 2004 May;10(9):2954-61.
10) Steve Chaplin MSc, MRPharmS and Anne SzarewskiPhD, MB BS, DRCOG, MFFP/Gardasil: first vaccine for human papillomavirus infection/ Prescriber 19 July 2007.
11) . , .. , .. , .. / / / (VIN)/ . 7, 4 2006. von Gruenigen VE, Gibbons HE, Gibbins K, Jenison EL, HopkinsMP /Surgical treatments for vulvar and vaginal dysplasia: a randomized controlled trial/Obstet Gynecol. 2007 Apr;109(4):942-7.
12) Manon van Seters, Marc van Beurden, Anton JM de Craen/ Is the assumed natural history of vulvar intraepithelialneoplasia 3 based on enoughevidence, A systematic review of 3322 published patients //Vulvar IntraepithelialNeoplasia:New concepts and strategy/Gynecol Oncol 2005;97:645 51.
13) Bruchim I,GotliebWH,Mahmud S,Tunitsky E,Grzywacz K,Ferenczy A.HPV-related vulvar intraepithelial neoplasia: outcome of different management modalities. Int J Gynaecol Obstet2007;99:237.
14) Tidy JA, SoutterWP, Luesley DM,MacLean AB,Buckley CH,Ridley CM.Management of lichen sclerosus and intraepithelial
15) neoplasia of the vulva in the UK. J R Soc Med1996;89:699701.
16) McNally OM,Mulvany NJ, Pagano R,Quinn MA,Rome RM.VIN 3: a clinicopathologic review. Int J Gynecol Cancer
17) Royal College of Obstetricians and Gynaecologists/ TheManagement of Vulval Skin Disorders / Green-top Guideline 58February 2011
18) Narayansingh GV,Cumming GP, Parkin DP,McConnell DT,Honey E,Kolhe PS. Flap repair: an effective strategy forminimising sexual morbidity associated with the surgicalmanagement of vulval intra epithelial neoplasia. J R CollSurg Edinb2000;45:814.
|
|
|
19) Terlou A,Hage JJ, van Beurden M. Skinning clitorectomy andskin replacement in women with vulvar intra-epithelialneoplasia. J Plast Reconstr Aesthet Surg2009;62:3415.
20) M. GENTILE, et al. /Adjuvant topical treatment with imiquimod 5%after excisional surgery for VIN 2/3/ European Review for Medical and Pharmacological Sciences/ 2014; 18: 2949-2952
